JAAD OnlineLack of specificity of cytokeratin-15 loss in scarring alopecias
References (8)
- et al.
Loss of cytokeratin-15 (CK15) expression is not specific for lichen planopilaris (LPP)
J Am Acad Dermatol
(2016) - et al.
Absence of catagen/telogen phase and loss of CK15 expression in hair follicles in lichen planopilaris
J Am Acad Dermatol
(2014) - et al.
Expression of hair follicle stem cells detected by CK15 stain: implications for pathogenesis of the scarring process in cutaneous lupus erythematosus
Br J Dermatol
(2009) - et al.
CK15 expression in central centrifugal scarring alopecia: new observations in normal and disease hair follicles
J Cutan Pathol
(2011)
Cited by (3)
Histologic and clinical cross-sectional study of chronic hair loss in patients with cutaneous chronic graft-versus-host disease
2019, Journal of the American Academy of DermatologyCitation Excerpt :All scalp biopsy specimens, furthermore, displayed a robust expression of CK15. Although lacking specificity, CK15 remains the best marker for bulge stem cells and is accordingly lost in many scarring alopecias but preserved in nonscarring forms.24,25 All specimens in this study showed strong CK15 expression, and therefore it is suggested that the hair follicle bulge stem cells are maintained in cGVHD patients with both patterns of alopecia despite the perifollicular fibrosis observed in patients with sclerotic alopecia.
Reply to: “Lack of specificity of cytokeratin-15 loss in scarring alopecias”
2017, Journal of the American Academy of DermatologyImmunostaining study of cytokeratins in human hair follicle development
2020, Anais Brasileiros de DermatologiaCitation Excerpt :Diseases such as hypotrichosis and monilethrix have already been linked to specific mutations of some CKs.9–11 Other diseases that may affect the hair follicle as lichen planus pilaris show an altered pattern in the expression of certain CKs that could be used as early markers for this disease.12,13 Thus, CKs may be targets for drug development and diagnostic methods that may assist in the early diagnosis and treatment of hair follicle diseases.
Funding sources: None.
Conflicts of interest: None declared.